The Antidepressant Desipramine and α2-Adrenergic Receptor Activation Promote Breast Tumor Progression in Association with Altered Collagen Structure
- 1 December 2013
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 6 (12) , 1262-1272
Abstract
Emotional stress activates the sympathetic nervous system (SNS) and release of the neurotransmitter norepinephrine to promote breast tumor pathogenesis. We demonstrate here that the metastatic mammary adenocarcinoma cell line 4T1 does not express functional adrenergic receptors (AR), the receptors activated by norepinephrine, yet stimulation of adrenergic receptor in vivo altered 4T1 tumor progression in vivo. Chronic treatment with the antidepressant desipramine (DMI) to inhibit norepinephrine reuptake increased 4T1 tumor growth but not metastasis. Treatment with a highly selective α2-adrenergic receptor agonist, dexmedetomidine (DEX), increased tumor growth and metastasis. Neither isoproterenol (ISO), a β-AR agonist, nor phenylephrine, an α1-AR agonist, altered tumor growth or metastasis. Neither DMI- nor DEX-induced tumor growth was associated with increased angiogenesis. In DMI-treated mice, tumor VEGF, IL-6, and the prometastatic chemokines RANTES, M-CSF, and MIP-2 were reduced. Tumor collagen microstructure was examined using second harmonic generation (SHG), a nonabsorptive optical scattering process to highlight fibrillar collagen. In DMI- and DEX-treated mice, but not ISO-treated mice, tumor SHG was significantly altered without changing fibrillar collagen content, as detected by immunofluorescence. These results demonstrate that α2-AR activation can promote tumor progression in the absence of direct sympathetic input to breast tumor cells. The results also suggest that SNS activation may regulate tumor progression through alterations in the extracellular matrix, with outcome dependent on the combination of adrenergic receptor activated. These results underscore the complexities underlying SNS regulation of breast tumor pathogenesis, and suggest that the therapeutic use of adrenergic receptor blockers, tricyclic antidepressants, and adrenergic receptor agonists must be approached cautiously in patients with breast cancer. Cancer Prev Res; 6(12); 1262–72. ©2013 AACR.Keywords
All Related Versions
This publication has 45 references indexed in Scilit:
- Collagen I fiber density increases in lymph node positive breast cancers: pilot studyJournal of Biomedical Optics, 2012
- Molecular Pathways: Beta-Adrenergic Signaling in CancerClinical Cancer Research, 2012
- Dexmedetomidine as an Adjuvant Analgesic for Intractable Cancer PainJournal of Palliative Medicine, 2011
- The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast CancerCancer Research, 2010
- Stromal gene expression predicts clinical outcome in breast cancerNature Medicine, 2008
- Phase matching considerations in second harmonic generation from tissues: Effects on emission directionality, conversion efficiency and observed morphologyOptics Communications, 2008
- Autonomic innervation and regulation of the immune system (1987–2007)Brain, Behavior, and Immunity, 2007
- Intrathecal infusion therapy with dexmedetomidine‐supplemented morphine in cancer painActa Anaesthesiologica Scandinavica, 2006
- Alpha‐2 and imidazoline receptor agonistsTheir pharmacology and therapeutic roleAnaesthesia, 1999
- Inhibition of Uptake of Tritiated-noradrenaline in the Intact Rat Brain by Imipramine and Structurally Related CompoundsNature, 1964